Élodie Vauléon

Inserm — France

Medicine · Health Sciences

33h-index4.2kcitations145works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(60), Brain Metastases and Treatment(22), Head and Neck Cancer Studies(19), Epigenetics and DNA Methylation(17), Meningioma and schwannoma management(10)

Publications140 total

BIOS-01. CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE
Neuro-Oncology·2025Open Access
P12.59.B CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE
Neuro-Oncology·2025Open Access
Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation
Neuro-Oncology·2025· 3 citedOpen Access
Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas <i>IDH</i>‐mutant and 1p/19q codeleted: A French POLA network study
Cancer·2025· 1 citedOpen Access
Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program
European Journal of Cancer·2024· 10 citedOpen Access
QOL-14. HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
Neuro-Oncology·2024Open Access
CTNI-14. RADIOTHERAPY VERSUS TMZ FOR HIGH-RISK LOW-GRADE GLIOMA. FINAL RESULTS AFTER MEDIAN FOLLOW-UP OF 13 YEARS OF PHASE III EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) STUDY
Neuro-Oncology·2024· 2 citedOpen Access
Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort
Neuro-Oncology·2024· 8 citedOpen Access
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
Journal of Clinical Oncology·2024· 20 cited
KS04.7.A HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
Neuro-Oncology·2024Open Access
Quelle peut être aujourd’hui la signification du serment d’Hippocrate dans une pratique oncologique universitaire ?
Éthique & Santé·2024
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.
Journal of Clinical Oncology·2024· 1 cited
Prise en compte des valeurs dans un Centre de Lutte Contre le Cancer : les identifier, les comprendre, les appliquer et les revendiquer. Place majeure de la bienveillance
SPIRE - Sciences Po Institutional REpository·2024
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network
Neuro-Oncology Advances·2024· 8 citedOpen Access
Transformation From Atypical to Anaplastic Metastatic Meningioma
Clinical Nuclear Medicine·2023· 3 cited
KS02.5.A OVERALL SURVIVAL ASSOCIATED WITH FIRST-LINE PCV OR TEMOZOLOMIDE IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH IDH-MUTANT, 1P/19Q CODELETED, GRADE 3 OLIGODENDROGLIOMA: ANALYSIS FROM THE POLA COHORT
Neuro-Oncology·2023· 3 citedOpen Access
Questionnement éthique et problématique interculturelle : le cas d’une patiente comorienne suivie en oncologie
Éthique & Santé·2023Open Access
Supplementary Materials and Methods, Supplementary Figures 1-7, Supplementary Tables 1-2 from CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma
2023Open Access
Supplementary Materials and Methods, Supplementary Figures 1-7, Supplementary Tables 1-2 from CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma
2023Open Access
Data from CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Alain Carpentier(19), François Ducray(14), Véronique Quillien(13), Olivier Chinot(13), Dominique Figarella‐Branger(12), Philippe Meneï(11), Tony Avril(10), Jean Mosser(10), Caroline Dehais(10), Marc Sanson(10), Ahmed Idbaïh(9), François Ghiringhelli(9), G. Noël(9), Philippe Colin(8), C. Desenclos(8), F. Dhermain(8), Thierry Faillot(8), Delphine Loussouarn(8), Carole Ramirez(8), Amandine Etcheverry(7)